Eris Brings Breakthrough Diabetes Therapy Within Reach with launch of weekly shot of Semaglutide starting at ₹220 per shot
India, March 21, 2026 : Eris Lifesciences Limited (“Eris Lifesciences” or the “Company”) (BSE: 540596; NSE: ERIS), a leading Indian branded formulations company, announced a breakthrough step in expanding access to advanced diabetes care with the launch of its generic Semaglutide under the brand ‘SUNDAE’ in India. Reinforcing its commitment as a responsible stakeholder in addressing the country’s growing…